PURPOSE: Assess fertility preservation (FP) measures chosen by patients newly diagnosed with malignancy and their outcomes. METHODS: Reproductive-age patients referred for FP underwent counseling and elected cryopreservation vs. no treatment. Outcome measures included ovarian stimulation, FP choice, oocytes/zygotes retrieved/cryopreserved and pregnancy outcome. RESULTS: From 2005 to 2012, 136 patients were counseled with 124 electing treatment: 83 oocyte-only, 21 oocyte + zygote and 20 zygote-only cryopreservation. Age, partnership and financial status factored into FP choice. Treatment was completed in 12 ± 2 days with 14 ± 11 metaphase-II oocytes harvested and cryopreserved/cycle. Eight patients returned to attempt pregnancy; three succeeded. CONCLUSIONS: Our data demonstrate that oocyte and/or zygote banking are feasible FP options for women with malignancy; given the choice, the majority elected oocyte cryopreservation, highlighting desire for reproductive autonomy. Continued growth and research, combined with interdisciplinary communication, will ensure that appropriate candidates are offered FP and the potential for future parenthood, an important quality-of-life marker for survivors.
PURPOSE: Assess fertility preservation (FP) measures chosen by patients newly diagnosed with malignancy and their outcomes. METHODS: Reproductive-age patients referred for FP underwent counseling and elected cryopreservation vs. no treatment. Outcome measures included ovarian stimulation, FP choice, oocytes/zygotes retrieved/cryopreserved and pregnancy outcome. RESULTS: From 2005 to 2012, 136 patients were counseled with 124 electing treatment: 83 oocyte-only, 21 oocyte + zygote and 20 zygote-only cryopreservation. Age, partnership and financial status factored into FP choice. Treatment was completed in 12 ± 2 days with 14 ± 11 metaphase-II oocytes harvested and cryopreserved/cycle. Eight patients returned to attempt pregnancy; three succeeded. CONCLUSIONS: Our data demonstrate that oocyte and/or zygote banking are feasible FP options for women with malignancy; given the choice, the majority elected oocyte cryopreservation, highlighting desire for reproductive autonomy. Continued growth and research, combined with interdisciplinary communication, will ensure that appropriate candidates are offered FP and the potential for future parenthood, an important quality-of-life marker for survivors.
Authors: Luis Chiva; Fernando Lapuente; Lucia González-Cortijo; Natalia Carballo; Juan F García; Alejandro Rojo; Antonio Gonzalez-Martín Journal: Gynecol Oncol Date: 2008-09-18 Impact factor: 5.482
Authors: J Byrne; S A Rasmussen; S C Steinhorn; R R Connelly; M H Myers; C F Lynch; J Flannery; D F Austin; F F Holmes; G E Holmes; L C Strong; J J Mulvihill Journal: Am J Hum Genet Date: 1998-01 Impact factor: 11.025
Authors: Barbara Luke; Morton B Brown; Logan G Spector; Judy E Stern; Yolanda R Smith; Melanie Williams; Lori Koch; Maria J Schymura Journal: J Assist Reprod Genet Date: 2016-02-03 Impact factor: 3.412
Authors: Kathryn Coyne; MacKenzie Purdy; Kathleen O'Leary; Jerome L Yaklic; Steven R Lindheim; Leslie A Appiah Journal: Front Public Health Date: 2014-12-05
Authors: Charlotte Sonigo; Nelly Frydman; Anne Mayeur; Vincent Puy; Victoria Windal; Laetitia Hesters; Vanessa Gallot; Alexandra Benoit; Michael Grynberg Journal: J Assist Reprod Genet Date: 2021-04-01 Impact factor: 3.357
Authors: Wael H Salem; Joe M Letourneau; Jessica Chan; Sai-Wing Chan; Marcelle Cedars; Mitchell P Rosen Journal: Contracept Reprod Med Date: 2017-03-02